Reed V. Tuckson, M.D. Joins Acasti's Board of Directors

Reed V. Tuckson, M.D. Joins Acasti's Board of Directors

LAVAL, Quebec, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti" or the
"Corporation") (Nasdaq:ACST) (TSX-V:APO), a subsidiary of Neptune Technologies
& Bioressources Inc., announces the appointment of Reed V. Tuckson, M.D. to
its Board of Directors. Dr. Tuckson's appointment increases Acasti's Board to
6 members, 4 of whom are independent directors.

"Dr. Tuckson is a recognized leader in his field," highlighted Mr. Henri
Harland, President and CEO of Acasti."He brings a strong reputation, deep
industry knowledge and valuable insight into health and medical care,
including the translation of science and technology into clinical
interventions.We look forward to his leadership in supporting and
communicating our science-based research and drug development activities on
omega-3 phospholipids."

"Throughout my career, whether as Commissioner of Public Health for the
District of Columbia, as Chief of Medical Affairs for the largest health
insurer in the United States, or as Managing Director of Tuckson Health
Connections, I have always sought to bring the most effective health solutions
to the greatest possible number of people," said Dr. Tuckson. "The
differentiated benefits of omega-3 phospholipids for pharmaceutical
applications are becoming better understood and I am excited about the
opportunities ahead for Acasti and its prescription drug candidate, CaPre^®. I
believe that CaPre^® has the potential to make a real difference in
cardiovascular care for people worldwide. I look forward to joining Acasti's
Board and supporting and communicating the developments that continue to be
key to the Corporation's continued success."

Dr. Tuckson is currently the Managing Director of Tuckson Health Connections,
LLC, a health and medical care consulting business.Previously, he served a
long tenure as Executive Vice President and Chief of Medical Affairs for
UnitedHealth Group, a Fortune 25 health and wellbeing company, which includes
the United States largest health insurer and the industry's most comprehensive
health services company.

Among his many committee memberships, Dr. Tuckson is member of the Advisory
Committee to the Director of the National Institutes of Health and is also an
active member of the Institute of Medicine of the National Academy of
Sciences. He also serves on the Boards of the American Telemedicine
Association, Howard University and Cell Therapeutics Inc., a public
corporation.Dr. Tuckson has been noted several times by Modern Healthcare
Magazine as one of the "50 Most Powerful Physician Executives" in healthcare
and Black Enterprise Magazine featured him as one of the "Most Powerful
Executives in Corporate America".

Dr. Tuckson is a graduate of Howard University, Georgetown University School
of Medicine, and the Hospital of the University of Pennsylvania's General
Internal Medicine Residency and Fellowship Programs, where he was also a
Robert Wood Johnson Foundation Clinical Scholar studying at the Wharton School
of Business.

About Acasti Pharma Inc.

Acasti is developing a product portfolio of proprietary novel long-chain
omega-3 phospholipids. Phospholipids are the major component of cell membranes
and are essential for all vital cell processes. They are one of the principal
constituents of High Density Lipoprotein (good cholesterol) and, as such, play
an important role in modulating cholesterol efflux. Acasti's proprietary novel
phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids
EPA and DHA, which have been shown to have substantial health benefits and
which are stabilized by potent antioxidants. Acasti is focusing initially on
treatments for chronic cardiovascular and cardiometabolic conditions within
the medical food and prescription drug markets.

Forward-Looking Statements

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. securities laws and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of Acasti to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. The forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from time to
time in Acasti's public securities filings with the Securities and Exchange
Commission and the Canadian securities commissions. Except as required by law,
Acasti disclaims any intention or obligation to update or revise any
forward-looking statements.

"Neither NASDAQ, the Toronto Stock Exchange, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of
this release."

CONTACT: Acasti Contact:
         Xavier Harland
         Chief Financial Officer
         +1.450.687.2262
         x.harland@acastipharma.com
         www.acastipharma.com
        
         Howard Group Contact:
         Dave Burwell
         +1.888.221.0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
 
Press spacebar to pause and continue. Press esc to stop.